Silexion Therapeutics CEO highlights successful pre-clinical study of SIL204: promising tumor inhibition in pancreatic, colorectal, and lung cancer models.SIL204 has shown noteworthy tumor inhibition in promising preclinical trials, displaying effectiveness against pancreatic, colorectal, and lung cancer models.
